MedTrace Logo

Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)

NCT03613857 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1022

Last updated 2019-01-14

No results posted yet for this study

Summary

In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogrel and ticagrelor 180 mg loading dose will be compared in acute coronary syndrome (ACS) patients undergoing PCI.

Conditions

Interventions

DRUG

Clopidogrel

8 tablets 75 mg clopidogrel loading dose before PCI

DRUG

Ticagrelor 90mg

2 tablets 90 mg brilique before PCI

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-15
Primary Completion
2018-07-28
Completion
2018-07-28
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03613857 on ClinicalTrials.gov